WilmerHale Settles Two Patent Infringement Suits for Palomar Against Candela and Syneron

Download IconDownload Print IconPrint

WilmerHale Settles Two Patent Infringement Suits for Palomar Against Candela and Syneron

Firm News

Related Solutions

A global team handling highly complex and sensitive matters in all aspects of litigation.
Combining our trial and appellate strengths allows us to shape litigation strategy from the outset to maximize the likelihood of ultimate success.
Clients trust us to protect their most important intellectual property matters.
Providing comprehensive solutions for the acquisition, enforcement and protection of IP.

By patenting their innovations, our clients increase the value of their intellectual property and enhance their ability to compete in the marketplace. We work with laboratory and research teams and R&D and product development groups to determine whether, when and where it is in our clients’ business and technical interests to seek patent protection. And we don’t just file patent applications. Drawing on our experience with patent litigation, corporate financings and technology transactions, we implement IP strategies that conserve resources, add measurable value and give our clients a cost-effective and commercially practical competitive edge.

We help clients obtain more than 750 US and foreign patents each year, covering innovations that span the technological spectrum, including aerospace, biochemistry, biotechnology, business methods, chemistry, computer science, fuel cells, genetics, high-speed data communication, integrated circuits, materials science, medical devices, nanotechnology, pharmaceuticals, semiconductor devices and processes, and software.

We also prepare and prosecute patent applications internationally under the Patent Cooperative Treaty and by working with a network of seasoned patent lawyers around the world. Our experience extends to appeals, interferences and opposition proceedings within the US Patent and Trademark Office, the US Court of Appeals for the Federal Circuit and the European Patent Office.

On September 16, WilmerHale client Palomar Medical Technologies, Inc., a leading researcher and developer of light-based systems for aesthetic treatments, and Syneron Medical Ltd., the leading global aesthetic device company, entered into a comprehensive settlement agreement ending the patent disputes between the companies in which WilmerHale had been representing Palomar and its co-plaintiff, The General Hospital Corporation, which operates Massachusetts General Hospital (MGH). The comprehensive settlement agreement includes two Non-Exclusive Patent License Agreements by Palomar with Candela Corporation (acquired by Syneron in January 2010) and Syneron.

Under the first agreement, Candela and Syneron agreed to pay Palomar $31 million in exchange for a non-exclusive, worldwide, fully paid-up, irrevocable license to US Patent Nos. 5,735,844 and 5,595,568 and foreign counterparts for their professional laser- and lamp-based hair removal systems. In addition, Palomar will receive a royalty-free license to certain Candela patents.

Under the second agreement, Palomar will grant to Syneron and affiliates a non-exclusive, royalty-bearing license in the United States to US Patent Nos. 5,735,844 and 5,595,568 for consumer home-use, lamp-based hair removal products. In addition, Palomar will receive a royalty-free license to certain Syneron and Candela patents. Full details are available here.

This settlement is just one in a series of victories we have obtained for Palomar. Since 1999, WilmerHale has represented Palomar and MGH in a number of disputes involving these patents. This representation has led to more than $125 million in licensing revenue for Palomar and MGH.

WilmerHale Partner Wayne Stoner was lead counsel on all matters for Palomar. His team included Partner Vinita Ferrera; Counsel Kate Saxton and Chris Noyes; Senior Associates Dimple Chaudhary and Sarah Petty; and Associate Leslie Stierman.

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.

I Accept Cancel